1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 2019, 69:7-34.
2. Janku F, Stewart DJ, Kurzrock R: Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol 2010, 7:401-414.
3. Chen X, Lu J, Wu Y, Jiang X, Gu Y, Li Y, Zhao H, Jin M: Genetic features and application value of next generation sequencing in the diagnosis of synchronous multifocal lung adenocarcinoma. Oncol Lett 2020, 20:2829-2839.
4. Rochigneux P, Garon EB: Are lung adenocarcinoma mutations shaping the immune microenvironment? Transl Cancer Res 2018, 7:S740-S742.
5. Wang Y, Zhang L, Chen Y, Li M, Ha M, Li S: Screening and identification of biomarkers associated with the diagnosis and prognosis of lung adenocarcinoma. J Clin Lab Anal 2020:e23450.
6. Ye J, Liu H, Xu ZL, Zheng L, Liu RY: Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma. J Clin Lab Anal 2019, 33:e22990.
7. Pfister KK, Shah PR, Hummerich H, Russ A, Cotton J, Annuar AA, King SM, Fisher EM: Genetic analysis of the cytoplasmic dynein subunit families. PLoS Genet 2006, 2:e1.
8. Wickstead B, Gull K: Dyneins across eukaryotes: a comparative genomic analysis. Traffic 2007, 8:1708-1721.
9. Sakakibara H, Oiwa K: Molecular organization and force-generating mechanism of dynein. FEBS J 2011, 278:2964-2979.
10. Rapali P, Szenes A, Radnai L, Bakos A, Pal G, Nyitray L: DYNLL/LC8: a light chain subunit of the dynein motor complex and beyond. FEBS J 2011, 278:2980-2996.
11. Yang Z, Vadlamudi RK, Kumar R: Dynein light chain 1 phosphorylation controls macropinocytosis. J Biol Chem 2005, 280:654-659.
12. Jaffrey SR, Snyder SH: PIN: an associated protein inhibitor of neuronal nitric oxide synthase. Science 1996, 274:774-777.
13. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A: The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 1999, 3:287-296.
14. Vadlamudi RK, Bagheri-Yarmand R, Yang Z, Balasenthil S, Nguyen D, Sahin AA, den Hollander P, Kumar R: Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell 2004, 5:575-585.
15. Mazumdar A, Kumar R: Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. FEBS Lett 2003, 535:6-10.
16. Rayala SK, Den Hollander P, Balasenthil S, Yang Z, Broaddus R, Kumar R: Functional regulation of oestrogen receptor pathway by the dynein light chain 1. EMBO Reports 2005, 6:538-544.
17. Nagai M, Yoneda Y: Small GTPase Ran and Ran-binding proteins. Biomol Concepts 2012, 3:307-318.
18. Azuma K, Sasada T, Takedatsu H, Shomura H, Koga M, Maeda Y, Yao A, Hirai T, Takabayashi A, Shichijo S, Itoh K: Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients. Clin Cancer Res 2004, 10:6695-6702.
19. Xia F, Lee CW, Altieri DC: Tumor cell dependence on Ran-GTP-directed mitosis. Cancer Res 2008, 68:1826-1833.
20. Abe H, Kamai T, Shirataki H, Oyama T, Arai K, Yoshida K: High expression of Ran GTPase is associated with local invasion and metastasis of human clear cell renal cell carcinoma. International Journal of Cancer 2008, 122:2391-2397.
21. Saxena S, Gandhi A, Lim PW, Relles D, Sarosiek K, Kang C, Chipitsyna G, Sendecki J, Yeo CJ, Arafat HA: RAN GTPase and Osteopontin in Pancreatic Cancer. Pancreat Disord Ther 2013, 3:113.
22. Kau TR, Way JC, Silver PA: Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 2004, 4:106-117.
23. Abe H, Kamai T, Shirataki H, Oyama T, Arai K, Yoshida K: High expression of Ran GTPase is associated with local invasion and metastasis of human clear cell renal cell carcinoma. Int J Cancer 2008, 122:2391-2397.
24. Goggolidou P, Stevens J, Agueci F, Keynton J, Wheway G, Grimes DT, Patel SH, Hilton H, Morthorst SK, Dipaolo A: ATMIN is a transcriptional regulator of both lung morphogenesis and ciliogenesis. Development 2014, 141:3966-3977.
25. Tang Z, Kang B, Li C, Chen T, Zhang Z: GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res 2019, 47:W556-W560.
26. Cline MS, Craft B, Swatloski T, Goldman M, Ma S, Haussler D, Zhu JC: Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser. Scientific Reports 2013, 3.
27. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al: STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Research 2015, 43:D447-D452.
28. Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, Kanellos I, Anastasopoulos IL, Maniou S, Karathanou K, Kalfakakou D, et al: DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucleic Acids Res 2015, 43:D153-159.
29. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13:2498-2504.
30. Janky R, Verfaillie A, Imrichova H, Van de Sande B, Standaert L, Christiaens V, Hulselmans G, Herten K, Naval Sanchez M, Potier D, et al: iRegulon: from a gene list to a gene regulatory network using large motif and track collections. PLoS Comput Biol 2014, 10:e1003731.
31. Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK, et al: A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell 2017, 171:1437-1452 e1417.
32. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al: The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935.
33. Grosdidier A, Zoete V, Michielin O: SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 2011, 39:W270-277.
34. He YJ, Meghani K, Caron MC, Yang C, Ronato DA, Bian J, Sharma A, Moore J, Niraj J, Detappe A, et al: DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells. Nature 2018, 563:522-526.
35. Becker JR, Cuella-Martin R, Barazas M, Liu R, Oliveira C, Oliver AW, Bilham K, Holt AB, Blackford AN, Heierhorst J, et al: The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity. Nat Commun 2018, 9:5406.
36. Dallol A, Hesson LB, Matallanas D, Cooper WN, O'Neill E, Maher ER, Kolch W, Latif F: RAN GTPase is a RASSF1A effector involved in controlling microtubule organization. Curr Biol 2009, 19:1227-1232.
37. Jeon H, Zheng LT, Lee S, Lee WH, Park N, Park JY, Heo WD, Lee MS, Suk K: Comparative analysis of the role of small G proteins in cell migration and cell death: cytoprotective and promigratory effects of RalA. Exp Cell Res 2011, 317:2007-2018.
38. Kurisetty VV, Johnston PG, Johnston N, Erwin P, Crowe P, Fernig DG, Campbell FC, Anderson IP, Rudland PS, El-Tanani MK: RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin. Oncogene 2008, 27:7139-7149.
39. Zaoui K, Boudhraa Z, Khalife P, Carmona E, Provencher D, Mes-Masson AM: Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion. Nat Commun 2019, 10:2666.
40. Deng L, Shang Y, Guo S, Liu C, Zhou L, Sun Y, Nie Y, Fan D, Lu Y, Guo X: Ran GTPase protein promotes metastasis and invasion in pancreatic cancer by deregulating the expression of AR and CXCR4. Cancer Biol Ther 2014, 15:1087-1093.
41. Ning J, Liu W, Zhang J, Lang Y, Xu S: Ran GTPase induces EMT and enhances invasion in non-small cell lung cancer cells through activation of PI3K-AKT pathway. Oncology Research 2014, 21:67-72.
42. Simula MP, Marin MD, Caggiari L, De Re V, Cannizzaro R, Canzonieri V: Comment re: Ran-GTP control of tumor cell mitosis. Cancer Res 2009, 69:1240; author reply 1240.
43. Morgan-Lappe SE, Tucker LA, Huang X, Zhang Q, Sarthy AV, Zakula D, Vernetti L, Schurdak M, Wang J, Fesik SW: Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res 2007, 67:4390-4398.
44. Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, et al: Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clin Cancer Res 2012, 18:380-391.
45. Yuen HF, Chan KK, Platt-Higgins A, Dakir el H, Matchett KB, Haggag YA, Jithesh PV, Habib T, Faheem A, Dean FA, et al: Ran GTPase promotes cancer progression via Met recepto-rmediated downstream signaling. Oncotarget 2016, 7:75854-75864.
46. Sheng KL, Pridham KJ, Sheng Z, Lamouille S, Varghese RT: Functional Blockade of Small GTPase RAN Inhibits Glioblastoma Cell Viability. Front Oncol 2018, 8:662.
47. Barres V, Ouellet V, Lafontaine J, Tonin PN, Provencher DM, Mes-Masson AM: An essential role for Ran GTPase in epithelial ovarian cancer cell survival. Mol Cancer 2010, 9:272.
48. Carty TJ, Marfat A, Moore PF, Falkner FC, Twomey TM, Weissman A: Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. Agents Actions 1993, 39:157-165.
49. Cersosimo RJ, Hong WK: Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 1986, 4:425-439.